Yuanbao Biotechnology completes nearly 100 million Yuan in Series A financing, focusing on musculoskeletal regenerative medical materials R&D

Recently, Hangzhou Yuanbao Biotechnology Co., Ltd. (hereinafter referred to as "Yuanbao Biotechnology") has successfully completed a nearly 100-million-yuan Series A financing round, led by Hotang Ventures with follow-up investments from Zhejiang Venture Capital and other investment institutions.

It is reported that the funds from this round of financing will be mainly used to advance the clinical application of the core product — "Bone02 Bone Adhesive," which can rapidly bond in a blood-wet environment and achieve complete biodegradability.

It is reported that Hangzhou Yuanbao Biotechnology Co., Ltd. is a clinical application-oriented enterprise specializing in the research and development of musculoskeletal regenerative medical materials. It was jointly established by Professor Fan Shunwu's orthopedic team from Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, and the medical device industry. The company adopts a "clinical-research-clinical" R&D model and has developed several innovative implantable material products for bone tissue repair, hard tissue adhesion, and soft tissue regeneration.

Its representative products include: a disposable gel patch former, recognized by regulatory authorities as the "first of its kind domestically" PRP (Platelet-Rich Plasma) patch preparation kit (Zhejiang Medical Device Registration No. 20252141621), which has obtained Zhejiang Province’s Innovative Class II Medical Device Certification, effectively solving the "last mile" challenge in the clinical application of PRP; porcine-derived bone repair material (National Medical Device Registration No. 20243131263) successfully overcomes interspecies immune rejection issues, achieving, for the first time both domestically and internationally, the complete replacement of allogeneic bone with porcine bone, filling the current market gap for bone defect repair materials.

Currently, Hangzhou Yuanbao Biotechnology Co., Ltd.'s bone adhesive technology enables seamless bonding of all sizes of bone fragments, reducing/avoiding the use of metal internal fixation, lowering the risk of foreign body reactions and infections, and greatly improving the efficiency of surgical treatment for comminuted fractures. In the future, it is expected to be applied in various clinical fields such as spinal fixation replacement and immediate oral implantation.